Published in Arthritis Rheum on October 01, 2008
PsA Secukinumab XCT Structural Progression Study | NCT03623867
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet (2011) 2.05
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther (2009) 2.05
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther (2009) 1.42
Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res Ther (2012) 1.26
The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol (2011) 1.24
Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond. Nat Rev Rheumatol (2010) 1.23
Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol (2010) 1.23
Inhibition of inflammation but not ankylosis by glucocorticoids in mice: further evidence for the entheseal stress hypothesis. Arthritis Res Ther (2012) 1.20
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis (2011) 1.18
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 1.18
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17
Developments in therapies for spondyloarthritis. Nat Rev Rheumatol (2012) 1.17
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis (2013) 1.03
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis (2013) 0.99
Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol (2010) 0.98
ERAP1 genetic variations associated with HLA-B27 interaction and disease severity of syndesmophytes formation in Taiwanese ankylosing spondylitis. Arthritis Res Ther (2012) 0.97
Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int (2011) 0.97
Disease modification in ankylosing spondylitis. Nat Rev Rheumatol (2010) 0.96
Diagnosis and treatment of enthesitis-related arthritis. Adolesc Health Med Ther (2012) 0.95
Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis (2011) 0.93
Psychological correlates of self-reported disease activity in ankylosing spondylitis. J Rheumatol (2010) 0.92
Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT. Ann Rheum Dis (2013) 0.92
Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis. Arthritis Rheum (2012) 0.92
Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis (2013) 0.89
Opinion: Perspectives on imaging in axial spondyloarthritis. Nat Rev Rheumatol (2013) 0.87
New evidence on the management of spondyloarthritis. Nat Rev Rheumatol (2016) 0.87
Advances in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol (2012) 0.87
The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther (2012) 0.86
Advances in managing ankylosing spondylitis. F1000Prime Rep (2014) 0.85
Improved precision of syndesmophyte measurement for the evaluation of ankylosing spondylitis using CT: a phantom and patient study. Phys Med Biol (2012) 0.85
Update on juvenile spondyloarthritis. Rheum Dis Clin North Am (2013) 0.85
What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther (2009) 0.85
Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther (2014) 0.84
Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years. Ann Rheum Dis (2013) 0.84
MRI and X-ray in axial spondyloarthritis: the relationship between inflammatory and structural changes. Arthritis Res Ther (2012) 0.81
Ankylosing spondylitis: patterns of radiographic involvement--a re-examination of accepted principles in a cohort of 769 patients. Radiology (2010) 0.81
Osteoimmunology and bone homeostasis: relevance to spondyloarthritis. Curr Rheumatol Rep (2013) 0.81
Ankylosis in ankylosing spondylitis: current concepts. Clin Rheumatol (2015) 0.81
Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy. Clin Rheumatol (2015) 0.81
Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis (2016) 0.80
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)? Arthritis Res Ther (2013) 0.80
Ultrasonography and color Doppler of proximal gluteal enthesitis in juvenile idiopathic arthritis: a descriptive study. Pediatr Rheumatol Online J (2011) 0.80
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2015) 0.80
Juvenile spondyloarthritis treatment recommendations. Am J Med Sci (2012) 0.79
Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis. Open Rheumatol J (2011) 0.79
Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther (2012) 0.79
Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol (2014) 0.78
Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts. Clin Rev Allergy Immunol (2016) 0.78
Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study. PLoS One (2015) 0.78
The role of bone morphogenetic proteins in ankylosing spondylitis. Ther Adv Musculoskelet Dis (2012) 0.78
How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis. Clin Dev Immunol (2013) 0.78
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]. Z Rheumatol (2014) 0.78
The Protective Effect of Chrysanthemum indicum Extract against Ankylosing Spondylitis in Mouse Models. Biomed Res Int (2017) 0.77
Old and new treatment targets in axial spondyloarthritis. RMD Open (2015) 0.77
Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci (2015) 0.77
Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77
Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician. Ther Adv Musculoskelet Dis (2010) 0.77
Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond. Nat Rev Rheumatol (2011) 0.77
[ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area]. Z Rheumatol (2013) 0.77
Impact of biological therapy on spondyloarthritis. Eur J Clin Pharmacol (2014) 0.76
Management of hip involvement in ankylosing spondylitis. Clin Rheumatol (2013) 0.76
Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatol Int (2015) 0.76
IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Res Ther (2016) 0.76
Anti-IL17A in Axial Spondyloarthritis-Where Are We At? Front Med (Lausanne) (2017) 0.75
TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis. Sci Rep (2016) 0.75
Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis. PLoS One (2016) 0.75
A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis. J Transl Med (2016) 0.75
Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials. Drug Des Devel Ther (2016) 0.75
Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. BMC Musculoskelet Disord (2015) 0.75
Aberrant axial mineralization precedes spinal ankylosis: a molecular imaging study in ank/ank mice. Arthritis Res Ther (2011) 0.75
A registry of ankylosing spondylitis registries and prospects for global interfacing. Curr Opin Rheumatol (2013) 0.75
Fat metaplasia on MRI of the sacroiliac joints increases the propensity for disease progression in the spine of patients with spondyloarthritis. RMD Open (2017) 0.75
Inhibition of Complement Retards Ankylosing Spondylitis Progression. Sci Rep (2016) 0.75
Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro. Drug Des Devel Ther (2016) 0.75
Immunohistological analysis of active sacroiliitis in patients with axial spondyloarthritis. Medicine (Baltimore) (2017) 0.75
Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol (2009) 0.75
Management of ankylosing spondylitis with infliximab. Open Access Rheumatol (2009) 0.75
Precision of syndesmophyte volume measurement for ankylosing spondylitis: a phantom study using high resolution CT. Conf Proc IEEE Eng Med Biol Soc (2009) 0.75
Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open (2017) 0.75
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol (2009) 0.75
Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. PLoS One (2015) 0.75
Digital tomosynthesis as a new diagnostic tool for evaluation of spine damage in patients with ankylosing spondylitis. Rheumatol Int (2016) 0.75
[Early therapy of axial spondyloarthritis and relevance of radiological progression]. Z Rheumatol (2012) 0.75
Physical activity in axial spondyloarthritis-tails from bench to bedside. Clin Rheumatol (2016) 0.75
Anti-TNFs in axial spondyloarthritis. Wien Med Wochenschr (2015) 0.75
[Ankylosing spondylitis. Target treatment criteria]. Z Rheumatol (2009) 0.75
Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther (2017) 0.75
Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents? Rheumatol Int (2016) 0.75
The synovio-entheseal complex in enthesoarthritis. Clin Exp Med (2015) 0.75
[High-resolution peripheral quantitative CT (HR-pQCT). New insights into arthritis]. Z Rheumatol (2013) 0.75
Mechanism of New Bone Formation in Axial Spondyloarthritis. Curr Rheumatol Rep (2017) 0.75
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med (2007) 3.81
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum (2005) 3.31
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67
Non-invasive measurement of brain viscoelasticity using magnetic resonance elastography. NMR Biomed (2008) 2.66
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum (2009) 2.45
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis (2010) 2.34
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24
The impact of aging and gender on brain viscoelasticity. Neuroimage (2009) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 2.14
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis (2012) 2.10
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum (2011) 2.10
Noninvasive assessment of the rheological behavior of human organs using multifrequency MR elastography: a study of brain and liver viscoelasticity. Phys Med Biol (2007) 2.08
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther (2009) 2.05
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum (2008) 2.04
EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis (2011) 2.04
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum (2006) 1.99
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.90
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum (2003) 1.79
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem (2002) 1.72
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis (2011) 1.68
In vivo viscoelastic properties of the brain in normal pressure hydrocephalus. NMR Biomed (2010) 1.67
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol (2003) 1.65
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol (2002) 1.63
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol (2007) 1.62
The natural history of spondylolysis and spondylolisthesis: 45-year follow-up evaluation. Spine (Phila Pa 1976) (2003) 1.59
The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol (2003) 1.58
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol (2006) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum (2002) 1.55
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.54
Stapled transanal rectal resection vs. transvaginal rectocele repair for treatment of obstructive defecation syndrome. Dis Colon Rectum (2009) 1.52
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum (2007) 1.49
Fractional encoding of harmonic motions in MR elastography. Magn Reson Med (2007) 1.49
MR elastography of the human heart: noninvasive assessment of myocardial elasticity changes by shear wave amplitude variations. Magn Reson Med (2009) 1.47
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.44
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol (2008) 1.43
Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis (2010) 1.43
Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41
Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med (2004) 1.41
Progression of rheumatoid arthritis on plain radiographs judged differently by expert radiologists and rheumatologists. J Rheumatol (2004) 1.41
Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. Rheumatology (Oxford) (2014) 1.40
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis (2010) 1.39
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.37
Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum (2006) 1.36
In vivo determination of hepatic stiffness using steady-state free precession magnetic resonance elastography. Invest Radiol (2006) 1.35
Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (2002) 1.35